Icotyde (Icotrokinra) Pricing 2026: Psoriasis Pill at About $8,500 a Month vs Sotyktu, Otezla, and Shots

Icotyde is a branded prescription pill, not a compounded peptide. The FDA approved Johnson & Johnson's Icotyde (icotrokinra) on March 18, 2026, for moderate to severe plaque psoriasis in adults and in children 12 and older who weigh at least 40 kg (88 pounds). Icotrokinra is a peptide, a short chain of amino acids, built to block the receptor for IL-23, an immune signal that drives psoriasis. The leading drugs that target the same pathway, Tremfya and Skyrizi, are antibodies given by injection. Icotyde is one 200 mg tablet a day, taken with water on an empty stomach, at least 30 minutes before eating. In the four Phase 3 trials behind the approval, 57% to 71% of patients on the drug had clear or almost clear skin at week 16. Nothing in this guide is compounded or sold for research.

J&J has not published a list price, so the best figures come from analysts and pharmacies. When the drug was approved, CNBC reported that J&J had not said what it would cost. In July 2026, analysts at Citizens put Icotyde's monthly wholesale acquisition cost at $8,285, or about $99,400 a year. The wholesale acquisition cost, or WAC, is the list price a drugmaker charges wholesalers before discounts and rebates, and almost nobody pays it directly. Pharmacy prices line up with that estimate: on October 5, 2026, GoodRx listed an average retail price of $10,681.56 for 30 tablets and a coupon price of $8,490.03.

A few terms, defined once. A pharmacy benefit manager, or PBM, is the company that runs a health plan's drug coverage and negotiates rebates; CVS Caremark, Express Scripts, and Optum Rx are the largest. A formulary is the PBM's list of covered drugs. Prior authorization means your doctor must get the plan's approval before the pharmacy can fill the prescription. Step therapy means the plan makes you try a cheaper drug first. Icotyde is a specialty drug, so a specialty pharmacy fills it and ships it to your home.

On the analyst figure, Icotyde's list price sits closer to the injections than to the older pills. Bristol Myers Squibb's Sotyktu, another psoriasis pill, has a WAC of $7,135.55 for 30 tablets, and Amgen's Otezla lists at $5,589.89 for a month's supply. Tremfya lists at $14,566.44 per injection and Skyrizi at $23,838.42 per dose, which works out to roughly $95,000 and $103,000 a year after the starting doses. With insurance, most of these gaps shrink: every one of these drugs has a manufacturer copay program that can bring the cost to $0 for people with commercial coverage.

For how Icotyde compares with shots and other pills, see our Icotyde guide. For the drug's two-year trial results, see our October 4 digest and the #icotrokinra and #psoriasis tag pages. For how prior authorization plays out at the pharmacy counter, see GLP-1 insurance coverage and prior authorization; the same rules apply to specialty psoriasis drugs. Prices below were checked on October 5, 2026.